Resources for Researchers
The National Emerging Infectious Diseases Laboratories (NEIDL) is part of a national network of secure facilities studying infectious diseases that are—or have the potential to become—major public health concerns
The Colorado State University Regional Biocontainment Laboratory is one of the NIAID-supported Regional Biocontainment Laboratories.
The Duke University School of Medicine, Duke Human Vaccine Institute (DHVI) Regional Biocontainment Lab (RBL) is one of the NIAID-supported Biocontainment Laboratories.
The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.
The Tufts New England Regional Biosafety Laboratory (RBL) is one of the NIAID-supported Regional Biocontainment Laboratories.
The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.
Biocontainment Laboratory: University of Alabama at Birmingham Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB)
The regional biocontainment laboratory at University of Alabama at Birmingham (UAB), called Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB), is one of the NIAID-supported Biocontainment Laboratories.
The University of Chicago Howard T. Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories. The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.
The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories.
Biocontainment Laboratory: University of Missouri Regional Laboratory for Infectious Disease Research (LIDR)
The University of Missouri Laboratory for Infectious Disease Research (LIDR) is one of the NIAID-supported Biocontainment Laboratories.
The University of Pittsburgh Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories.
The University of Tennessee Regional Biocontainment Laboratory (RBL) is one of the NIAID-supported Biocontainment Laboratories.
As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms u
This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical pr
Heterogeneity in Human Immune Cells is a website providing interactive figures (iFigs) for a recent study of protein expression heterogeneity in human immune cells conducted by Dr.
This service can be used to develop and perform a variety of analytical assays to assess the properties of drug substances and their formulations.
This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
This service provides evaluation of products in animal efficacy models. A product must demonstrate a potent and selective activity profile in vitro against the HIV strain used in the model prior to its acceptance as a candidate for this service.
This service can be used to provide pharmacokinetic and safety assessments of products in mice, rats, rabbits, dogs, and nonhuman primates.
The Immcantation framework is developed as a start-to-finish analytical ecosystem for large-scale characterization of B cell receptor (BCR) and T cell receptor (TCR) repertoires from high-throughput adaptive immune receptor repertoire sequencing (AIRR-seq) datasets.
Researchers involved with the NIAID Clinical Genomics Program study many diseases of the immune system that are rare and not well understood but often shed light on basic immune function and more common immune disorders.
This Gene Set Enrichment-type test designed for analysis of microarray and RNASeq data is designed to provide a faster, more accurate, and easier to understand test for gene expression studies. QuSAGE extends previous methods with a complete probability density function (PDF).
The Throughput Ranking by Iterative Analysis of Genomic Enrichment (TRIAGE) platform is designed to facilitate prediction, analysis, and hypothesis generation from High-throughput genomic studies such as those done by CRISPR, RNAseq, proteomic, and clinical sequencing studies.
The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).